14 employees
Bexson Biomedical is developing a unique formulation of ketamine for chronic and acute pain disorders.
2017
$4.8M
from 2 investors over 2 rounds
Bexson Biomedical raised $4.8M on February 2, 2021
Investors: Noetic Fund and Lionheart Ventures